Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.05 - $2.77 $36,900 - $49,860
-18,000 Reduced 75.31%
5,900 $15,000
Q2 2024

Aug 14, 2024

SELL
$2.22 - $5.89 $5,772 - $15,314
-2,600 Reduced 9.81%
23,900 $53,000
Q1 2024

May 15, 2024

BUY
$1.46 - $5.91 $27,740 - $112,290
19,000 Added 253.33%
26,500 $141,000
Q4 2023

Feb 14, 2024

SELL
$0.96 - $1.55 $12,288 - $19,840
-12,800 Reduced 63.05%
7,500 $11,000
Q3 2023

Nov 14, 2023

BUY
$1.38 - $2.18 $14,075 - $22,236
10,200 Added 100.99%
20,300 $28,000
Q2 2023

Aug 14, 2023

BUY
$1.37 - $1.95 $8,768 - $12,480
6,400 Added 172.97%
10,100 $14,000
Q1 2023

May 15, 2023

BUY
$1.45 - $2.09 $1,740 - $2,508
1,200 Added 48.0%
3,700 $6,000
Q4 2022

Feb 14, 2023

SELL
$1.22 - $1.66 $65,026 - $88,478
-53,300 Reduced 95.52%
2,500 $3,000
Q3 2022

Nov 14, 2022

BUY
$1.54 - $3.21 $85,932 - $179,118
55,800 New
55,800 $86,000

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $110M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.